RTP Mobile Logo
Integration of Tissue Biomarker Assays into Protocol and Nonprotocol Management of Lung Cancer
Released December 2009

Proceedings from a CME symposium held during the 13th World Conference on Lung Cancer. Special Feature: Atlas of Molecular Oncology PowerPoint slide sets. (Audio and Text Content)

CE Disclosures and Faculty Information

  • This presentation was selected by the 13th World Conference on Lung Cancer Programme Committee as an independent educational activity held in conjunction with the 13th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by the IASLC.

    OVERVIEW OF ACTIVITY

    Lung cancer is the leading cause of cancer mortality in the United States in both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85 percent of patients who develop lung cancer will die from it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on patient outcomes. However, with the advent of targeted biologic agents in addition to molecular and clinical biomarkers, recent improvements have been seen in time to progression and survival in lung cancer clinical trials. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with experts’ perspectives on the findings, this CME program is designed to assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for the care of patients with lung cancer.

    LEARNING OBJECTIVES

    • Identify somatic gene mutations that may be utilized to predict lung tumor response or resistance to EGFR-directed therapy.
    • Incorporate clinical and molecular biomarkers into the selection of optimal treatment strategies for patients with advanced non-small cell lung cancer (NSCLC).
    • Recognize the role of target population enrichment in the tailored investigation of biologic therapy for localized and metastatic lung cancer.
    • Explain how tumor histology and/or receptor expression profile may affect chemotherapy sensitivity.
    • Apply the results of emerging research to refine the use of anti-angiogenic agents in the treatment of NSCLC.
    • Recall the design and eligibility criteria for ongoing clinical trials in NSCLC, and counsel appropriate patients for study participation.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains audio, print and slide components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr LynchConsulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Infinity Pharmaceuticals Inc, Merck and Company Inc; Royalties for EGFR Testing Patent: Genzyme Corporation. Dr MillerConsulting Agreements: Abraxis BioScience, Agennix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Facet Biotech Corporation, Genentech BioOncology, ImClone Systems Incorporated, Lilly USA LLC, Sanofi-Aventis; Scientific Advisory Board: Cylene Pharmaceuticals. Dr MokAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, Eisai Inc, GlaxoSmithKline, Lilly USA LLC, Roche Laboratories Inc; Consulting Agreements: Pfizer Inc, Roche Laboratories Inc; Paid Research: AstraZeneca Pharmaceuticals LP; Speakers Bureau: Lilly USA LLC, Roche Laboratories Inc. Dr SchillerAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, ImClone Systems Incorporated, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis; Paid Research: Pfizer Inc. Prof SoriaConsulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, Biogen Idec, Bristol-Myers Squibb Company, Lilly USA LLC, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Wyeth. Dr Schneider (featured on the accompanying Atlas of Molecular Oncology PowerPoint program) — Advisory Committee: Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline; Paid Research: Genentech BioOncology.

    EDITORNeil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Merck and Company Inc, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Wyeth.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This program is supported by an educational grant from Genentech BioOncology & OSI Oncology.

    Last review date: December 2009
    Expiration date: December 2010

Acknowledge and close